Victory Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$270K Sell
15,575
-199,577
-93% -$3.45M ﹤0.01% 2181
2025
Q1
$4.71M Sell
215,152
-347,117
-62% -$7.59M ﹤0.01% 1300
2024
Q4
$17.9M Buy
562,269
+150,363
+37% +$4.8M 0.02% 889
2024
Q3
$11.9M Sell
411,906
-49,960
-11% -$1.44M 0.01% 1045
2024
Q2
$17.7M Sell
461,866
-30,031
-6% -$1.15M 0.02% 850
2024
Q1
$28.9M Sell
491,897
-124,375
-20% -$7.31M 0.03% 682
2023
Q4
$36.9M Sell
616,272
-122,239
-17% -$7.32M 0.04% 544
2023
Q3
$28.1M Buy
738,511
+337,554
+84% +$12.8M 0.03% 624
2023
Q2
$36.5M Sell
400,957
-161,212
-29% -$14.7M 0.04% 535
2023
Q1
$37.1M Buy
562,169
+131,618
+31% +$8.68M 0.04% 543
2022
Q4
$22.3M Sell
430,551
-242,500
-36% -$12.5M 0.03% 737
2022
Q3
$46M Sell
673,051
-25,120
-4% -$1.72M 0.05% 488
2022
Q2
$31.6M Sell
698,171
-626,793
-47% -$28.3M 0.04% 643
2022
Q1
$67.2M Sell
1,324,964
-241,013
-15% -$12.2M 0.07% 406
2021
Q4
$74M Sell
1,565,977
-204,830
-12% -$9.68M 0.07% 395
2021
Q3
$58.4M Buy
1,770,807
+114,519
+7% +$3.77M 0.06% 481
2021
Q2
$105M Sell
1,656,288
-277,492
-14% -$17.5M 0.1% 254
2021
Q1
$83M Buy
1,933,780
+23,803
+1% +$1.02M 0.09% 332
2020
Q4
$109M Sell
1,909,977
-235,485
-11% -$13.5M 0.12% 227
2020
Q3
$64.7M Buy
2,145,462
+180,917
+9% +$5.46M 0.08% 350
2020
Q2
$64.2M Sell
1,964,545
-1,768,285
-47% -$57.8M 0.09% 338
2020
Q1
$100M Buy
3,732,830
+1,563,481
+72% +$41.9M 0.08% 337
2019
Q4
$66.4M Buy
2,169,349
+367,907
+20% +$11.3M 0.08% 369
2019
Q3
$43.4M Buy
1,801,442
+139,239
+8% +$3.35M 0.06% 504
2019
Q2
$42.1M Sell
1,662,203
-26,460
-2% -$670K 0.09% 367
2019
Q1
$32.9M Buy
1,688,663
+300,900
+22% +$5.87M 0.07% 413
2018
Q4
$18.3M Buy
1,387,763
+40,010
+3% +$528K 0.05% 571
2018
Q3
$24M Buy
1,347,753
+415,000
+44% +$7.38M 0.05% 559
2018
Q2
$20.5M Buy
932,753
+559,913
+150% +$12.3M 0.04% 592
2018
Q1
$8.24M Buy
+372,840
New +$8.24M 0.02% 775